StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

Kyverna Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

No price to sales ratio figures for Kyverna Therapeutics

Kyverna Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Kyverna Therapeutics figures

See a number that looks wrong?